Skip to content

Contribution of an Off-the-shelf Carbon Ankle Foot Orthosis (AFO) in the Management of Walking Functional Impairment

Single Case Experimental Design (SCED) Comparing an Off-the-shelf Carbon Ankle Foot Orthosis (SPRYSTEP) Versus an off-the Shelf Standard Plastic Ankle Foot Orthosis in the Treatment of Walking Functional Impairment

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05131399
Acronym
DEFISTEP
Enrollment
20
Registered
2021-11-23
Start date
2022-02-28
Completion date
2024-11-30
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathy (Disorder)

Keywords

orthosis, functional walking impairment, foot drop, rehabilitation, GAS

Brief summary

The objective of this study is to assess the superiority in achieving personal goals (set by the patient and the medical team) according to the GAS scale (Goal Attainment Scaling) while wearing the carbon medical device Ankle Foot Orthosis (AFO) compared to a standard plastic ankle foot orthosis.

Detailed description

Foot drop is a symptom observed in various pathologies including neuro-muscular pathologies of peripheral or central origin. It is a walking disability, causing a deterioration in the patients autonomy and quality of life. The current medical strategy focuses on various off-the-shelf or custom made devices, depending on the walking functional impairment and the characteristics of foot deformities. The objective of this study is to assess the superiority in achieving personal goals (set by the patient and the medical team) according to the GAS scale (Goal Attainment Scaling) while wearing the carbon medical device ankle foot orthosis compared to a standard plastic ankle foot orthosis.

Interventions

DEVICEPhase A1

Plastic standard ankle foot orthosis

DEVICEPhase B1

carbon medical device ankle foot orthosis

DEVICEPhase A2

Plastic standard ankle foot orthosis

DEVICEPhase B2

carbon medical device ankle foot orthosis

Sponsors

Thuasne
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective, multicenter, interventional study, SCED design in ABAB introduction/withdrawal. The timing of the transition from one phase to the next will be randomized. The duration of each of the phases (A1, B1, A2, B2) will therefore be defined randomly, while maintaining a total duration of 12 weeks for each study schema.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with a foot levator muscles impairment (single or bilateral drop foot) and / or instability of the back of the foot, associated with a deficit of the triceps * Patient with inability to stand on tip-toe on one foot * Patient having signed a free and informed consent * Patient affiliated or entitled to a social security scheme

Exclusion criteria

* Patient with fixed varus-equine foot * Patient with an unstable skin condition (whether or not treated with additional treatment that may change the footwear) * Patient with a a foot levator muscles impairment with a deficiency of the quadriceps and hamstrings (knee involvement) * Patient with uncontrolled spasticity * Patient for whom foot surgery is planned during the study * Patient with one of the contraindications to the use of carbon medical device, indicated in the instructions for use * Patient with one of the contraindications to the use of the standard plastic ankle foot orthosis, indicated in the instructions for use * Patient with orthopedic comorbidities affecting the musculoskeletal system * Pregnant woman * Patient with major cognitive impairment incompatible with participation in a clinical trial * Patient participating in another clinical investigation conducted to establish the compliance of a MD impacting the evaluation criteria * Patient who cannot be followed for 12 weeks * Vulnerable patient according to article L1121-6 of the public health code, persons subject to a measure of judicial protection or unable to consent freely

Design outcomes

Primary

MeasureTime frameDescription
Comparison of the ability to achieve personal goals while wearing carbon or standard plastic ankle foot orthosis3 times a week during 12 weeksPersonal goals achievement is evaluated via the Goal attainment scaling (GAS). Before starting the study, three personal objectives are defined according to patients needs and investigator review. Raw scores ranging from -3 (degradation) to +2 (maximum achievement of the objective) are defined: -3 corresponding to degradation -2 corresponding to the initial state -1 corresponding to a partial objective achievement 0 corresponding to the total objective achievement +1 corresponding to a better objective achievement +2 corresponding to the maximum objective achievement. The GAS is filled 3 times a week during 12 weeks.

Secondary

MeasureTime frameDescription
Comparison of patients walking perimeter while wearing carbon or standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Walking perimeter is evaluated via the Six-minute walk test (6MWT), that measures the distance (in meters) during a 6 minutes walk.
Comparison of patients fatigue while wearing carbon or standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Patient's fatigue perception is assessed by the patient via the Borg Rating of Perceived Exertion (RPE) scale following mobility and walking perimeter tests The effort rating is based on a scale of 6 to 20 (6, which is no effort, to 20, which is maximum effort).
Comparison of patients stability while wearing carbon or standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Patient's stability is assessed by 2 means: 1. via the Timed Up and Go test : time (in seconds) to realize the test. The patient should stand up from a chair, walk a distance of three meters, turn around, then walk back to the chair and sit down. These tasks should be performed at a comfortable and safe speed. 2. via the number of falls recorded during each phase and their context
Comparison of patients disability evolution according to the investigator while wearing carbon or standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Doctors' opinion on the Patients disability evolution is measured by the Clinical Global Impression - Improvement (CGI-I) questionnaire. The scale has 7 levels of answer from very strongly improved which is the better outcome (= 1 point) to very strongly aggravated which is the worst outcome (= 7 points) .Intermediate levels are: Significantly improved (= 2 points) ; Slightly improved (= 3 points) ; No improvement (=4 points) ; Slightly worsen (=5 points) ; Seriously worsen ( = 6 points). The highest score corresponds to the most impairment in quality of life.
Comparison of patients mobility while wearing carbon or standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12).Mobility is evaluated via staircase tests: Time (in minutes) to go up and down 10 steps
Comparison of pain, gait and balance evolution according to the patient while wearing carbon or standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Pain level is measured by Visual Analogic Scale (VAS) completed by the patient : 0 corresponds to no pain (better outcome) and 10 to maximum pain (worst outcome). Natural gait and confidence in walking are measured by Visual Analogic Scale (VAS) completed by the patient : 0 corresponds to no natural gait or no confidence (worst outcome) and 10 to better natural gait and better confidence (better outcome). Balance is measured by Visual Analogic Scale (VAS) completed by the patient : 0 corresponds to no balance (worst outcome) and 10 to maximum balance (better outcome).
Comparison of tolerance of carbon and standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Tolerance is measured by reported adverse events. Number and type of serious and non-serious Adverse Device Effects (ADE) are reported.
Comparison of acceptability and compliance with carbon and standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Cumulative wearing time of the devices under study (indicated by a thermal button inserted into the device) is collected during each phase. Specific questions on compliance are also asked by the investigator to the patient during the various visits.
Patients satisfaction with carbon and standard plastic ankle foot orthosisV4 at 12 weeksPatients satisfaction is evaluated at the end of phase B2 regarding the use of the study devices via the Technology part of the evaluation towards a technical aid questionnaire (8 questions) and a specific questionnaire.
Comparison of patients disability evolution according to the patient while wearing carbon or standard plastic ankle foot orthosisVisits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)Patient's opinion on his disability evolution is measured by the Global Impression of Change (PCI-C). The scale has 7 levels from no change or condition has got worsed(worse outcome) to a great deal better, and a considerable improvement that has made all the difference ( better outcome). Intermediate levels are: almost the same, hardly any change at all; a little better, but no noticeable change, somewhat better, but the change has not made any real difference; moderately better, and a slight but noticeable change; better, and a definite improvement that has made a real and worthwhile difference.

Countries

France

Contacts

Primary ContactPhilippe THOUMIE, MD PhD
philippe.thoumie@aphp.fr(0)140193534
Backup ContactAstrid PICOLET
astrid.picolet@thuasne.fr(0)640392490

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026